Business · 11/03/2024Updated: 10/17/2026 · 1 min read
FDA Revokes Emergency Use Authorization for Eli Lilly's COVID-19 Treatment
Summary
The FDA has revoked the Emergency Use Authorization for bamlanivimab and etesevimab administered together, issued to Eli Lilly and Co., due to the reasons outlined in the document, effective December 14, 2023.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →